Last reviewed · How we verify

Low-dose Dexmedetomidine

Tang-Du Hospital · FDA-approved active Small molecule

Low-dose dexmedetomidine is a selective alpha-2 adrenergic agonist that produces sedation, analgesia, and anxiolysis with minimal respiratory depression.

Low-dose dexmedetomidine is a selective alpha-2 adrenergic agonist that produces sedation, analgesia, and anxiolysis by activating presynaptic alpha-2 receptors in the central nervous system. Used for Sedation in intensive care unit (ICU) patients, Procedural sedation, Anxiolysis and analgesia in perioperative settings.

At a glance

Generic nameLow-dose Dexmedetomidine
Also known asYisi
SponsorTang-Du Hospital
Drug classAlpha-2 adrenergic agonist
TargetAlpha-2 adrenergic receptor
ModalitySmall molecule
Therapeutic areaAnesthesia/Sedation
PhaseFDA-approved

Mechanism of action

Dexmedetomidine binds to alpha-2 adrenergic receptors in the central nervous system, particularly in the locus coeruleus, producing dose-dependent sedation and analgesia. At low doses, it provides anxiolytic and analgesic effects while preserving airway reflexes and maintaining spontaneous breathing, making it suitable for conscious sedation and perioperative use.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results